In brief: MGF (Mechano Growth Factor) is an endogenous messenger substance produced in muscle tissue when it is stressed or injured. Research investigates whether MGF supports muscle regeneration. Important upfront: MGF is not an approved medicine, there are no controlled human trials, and its use is strictly prohibited in sports.
What is MGF?
MGF (Mechano Growth Factor), also known as IGF-1Ec, is a naturally occurring splice variant of insulin-like growth factor 1 (IGF-1) that is locally expressed in skeletal muscle and tissue following mechanical load, stretching, or injury, acting as a rapid signal for muscle repair and stem cell activation.
Discovered in the early 2000s, it arises through alternative splicing of the IGF-1 gene. Unlike systemic IGF-1Ea, which circulates throughout the body via the liver, MGF acts locally. A critical issue in the scientific literature is the problematic nomenclature: the term "MGF" is often used ambiguously. Researchers frequently fail to distinguish whether they are referencing the full-length MGF molecule or solely the 24-amino-acid E-peptide, making direct comparisons between studies highly difficult.
| Agent | Class / Mechanism | Effect Size / Evidence | Approval Status |
|---|---|---|---|
| Native MGF (IGF-1Ec) | Local IGF-1 splice variant (E-peptide) | Strong preclinical data, 0 human trials | Unapproved / WADA Prohibited |
| PEG-MGF | PEGylated full-length MGF peptide (longer half-life) | Widely used in research/anecdotal, 0 human trials | Unapproved / WADA Prohibited |
| Systemic IGF-1 | Full-length systemic growth factor | Clinical data exists, systemic anabolic effects | Approved for specific rare diseases |
How does MGF work?
MGF operates through a dual mechanism where the full-length molecule binds to the IGF-1 receptor to promote protein synthesis, while its specific C-terminal E-peptide acts autonomously to rapidly activate dormant muscle satellite stem cells, increasing their multiplication and fusion potential without causing premature maturation.
When muscle fibers are damaged, the localized MGF pulse triggers the proliferation of these progenitor cells. In laboratory settings (in vitro), this specific mechanism has been shown to delay the replicative senescence (the natural end of a cell's ability to divide) of muscle cells by an estimated 14 %.
Because native MGF is broken down extremely quickly in the body, researchers and unregulated markets frequently utilize PEG-MGF (PEGylated Mechano Growth Factor). Attaching a polyethylene glycol molecule to the peptide significantly increases its stability, plasma half-life, and overall duration of action in the body.
How effective is MGF?
The effectiveness of MGF is currently supported almost exclusively by preclinical models-such as in vitro cell cultures and animal experiments-which demonstrate muscle regeneration, reduced oxidative stress, and tissue protection, whereas robust clinical trials proving these benefits in humans are completely absent.
Animal models indicate that MGF can reduce inflammatory hormones and oxidative stress following injury. Beyond skeletal muscle, research explores its role in cartilage repair, wound healing, and neuroprotection following brain injuries. However, the scientific consensus is not absolute.
A notable contradiction exists in the broader literature: while several early studies confirmed that the E-peptide successfully activates muscle stem cells, a subsequent study by Fornaro et al. found that the MGF peptide had no observable effect on muscle myoblasts or primary muscle stem cells. This discrepancy, possibly linked to nomenclature issues, means its definitive biological efficacy remains debated.
Dosage: what the studies show - and the progression
There is no clinically validated or approved human dosage for MGF, meaning any dosing data originates strictly from experimental literature and anecdotal bodybuilding protocols, where users typically utilize the more stable PEG-MGF variant rather than the rapidly degraded native peptide to sustain biological activity.
| Phase / Context | Agent | Anecdotal Dose | Goal / Note |
|---|---|---|---|
| Post-Training (Anecdotal) | Native MGF | 100 - 300 mcg | Injected locally; rapidly degraded |
| Weekly Cycle (Anecdotal) | PEG-MGF | 200 - 400 mcg | Longer half-life, systemic reach |
| Clinical Validation | N/A | None | No established safe human dose |
Handling & Storage
Because exogenous MGF is typically synthesized as a lyophilized (freeze-dried) research chemical, proper handling requires careful reconstitution with sterile bacteriostatic water and strict storage in a refrigerated environment to prevent the rapid degradation and loss of biological activity inherent to unmodified peptide chains.
Once reconstituted, peptide stability is highly sensitive to temperature fluctuations and light exposure. Furthermore, because products sold online are marketed strictly as "research chemicals," they bypass pharmaceutical manufacturing standards, carrying inherent risks of contamination or inaccurate dosing that require rigorous harm-reduction awareness.
Side effects and common mistakes
The side effect profile of exogenous MGF is poorly understood due to a lack of human trials, but theoretical and anecdotal evidence points to significant risks including potentially cancer-promoting (carcinogenic) effects, alongside common acute reactions such as injection site irritation, dizziness, and nausea.
Due to its potent growth-factor properties, exogenous MGF is strictly contraindicated for individuals with pre-existing conditions such as cancer, diabetes, or severe kidney disease. Theoretical interactions with blood thinners and diabetes medications are also noted within harm-reduction circles.
- Confusing native MGF with PEG-MGF: Native MGF has a half-life of mere minutes; expecting prolonged effects without PEGylation is a common misunderstanding.
- Ignoring cancer risks: As a potent tissue-growth promoter, utilizing MGF with undiagnosed tumors or active cancers poses severe theoretical risks.
- Assuming human efficacy from mouse data: Many users extrapolate muscle regeneration results directly from rodent studies, ignoring the complete lack of human pharmacokinetic data.
Approval and legal status
MGF is globally unapproved as a medical treatment for any condition in regions including the EU, Germany, and the USA, and because of its highly anabolic and muscle-repairing properties, it is explicitly prohibited by the World Anti-Doping Agency (WADA) for all competitive athletes.
Commercially, MGF and PEG-MGF are sold exclusively as unregulated "research chemicals" or "investigational compounds," meaning they bypass the strict safety and efficacy requirements of agencies like the FDA or EMA. While possession for research purposes may not be strictly illegal depending on the jurisdiction, utilizing these unapproved products for human enhancement carries substantial health risks and violates sporting regulations globally.
Evidence at a glance
Editorial, sourced from primary literature - not medical advice.
Related peptides
Sources
- Hameed M et al. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol 2004. PMID 14565994; doi:10.1113/jphysiol.2003.051722
- Hanssen KE et al. The effect of strength training volume on satellite cells, myogenic regulatory factors, and growth factors. Scand J Med Sci Sports 2013. PMID 22417199; doi:10.1111/j.1600-0838.2012.01452.x
- Xiao W et al. Overload training inhibits phagocytosis and ROS generation of peritoneal macrophages: role of IGF-1 and MGF. Eur J Appl Physiol 2013. PMID 22592456; doi:10.1007/s00421-012-2418-5
- Wilborn CD et al. Effects of different intensities of resistance exercise on regulators of myogenesis. J Strength Cond Res 2009. PMID 19826309; doi:10.1519/JSC.0b013e3181bab493
- Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages - PubMed
- Mechano-Growth Factor: an important cog or a loose screw in ... - PMC
- MGF: a local growth factor or a local tissue repair factor?
- Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration - PMC
- Mechano Growth Factor peptide (MGF), the COOH terminus of ...
- Mechano growth factor - Wikipedia
Still experimental evidence (level < 3) - we deliberately do not provide an injection calculation here.